nference and BeiGene Collaborate on B-Cell Cancer Research

nference and BeiGene have announced a collaboration to enhance research on B-cell cancers using AI technology, focusing on chronic lymphocytic leukemia and small lymphocytic lymphoma.

nference and BeiGene have announced a collaboration to advance research in B-cell cancers, specifically targeting chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This partnership, announced in a press release, will utilize nference's proprietary Agentic AI platform to analyze real-world data from over 700 patient charts. The goal is to identify treatment patterns and improve clinical practices for these malignancies, which affect lymphocytes, a type of white blood cell crucial to immune function. CLL is noted as the most common adult leukemia in the U.S., highlighting the importance of this research initiative.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following us on social media:

AI Brief
AI Brief (X)

More from: Healthcare & Life Sciences

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like